US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
NVDA
$233.95
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
JNJ
$256.03
▲+0.00%
SPCX
$158.96
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
NVDA
$233.95
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
JNJ
$256.03
▲+0.00%
SPCX
$158.96
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Junshi Biosciences
< Previous
1
2
Next >
Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates
August 26, 2026
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC
July 21, 2026
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)
July 01, 2026
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
May 26, 2026
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma
May 21, 2026
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026
April 20, 2026
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates
March 13, 2026
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications
March 09, 2026
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
February 24, 2026
From
Junshi Biosciences
Via
GlobeNewswire
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
December 05, 2025
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
December 05, 2025
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
November 24, 2025
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
October 16, 2025
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
September 07, 2025
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates
August 26, 2025
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma
August 08, 2025
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Ongericimab’s sNDA Approval in China
May 27, 2025
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
April 25, 2025
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
March 28, 2025
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Toripalimab’s Approval in Singapore
March 26, 2025
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma
March 23, 2025
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe
January 20, 2025
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Toripalimab’s Approval in Australia
January 17, 2025
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab
November 16, 2024
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR
October 15, 2024
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab
September 24, 2024
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
August 30, 2024
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma
August 12, 2024
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
July 26, 2024
From
Junshi Biosciences
Via
GlobeNewswire
Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
July 17, 2024
From
Junshi Biosciences
Via
GlobeNewswire
< Previous
1
2
Next >
